Therapeutic fibrinolysis. What should follow?
Stead
N W
NW
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005167:Factor VII / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008074:Lipoproteins / Q000627:therapeutic use*; D012008:Recurrence; D013925:Thromboplastin / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D005167:Factor VII; D013925:Thromboplastin